Compare Alcon AG (ALC) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Vanguard Mega Cap Growth ETF — how do they compare? Alcon AG trades at $73.85 (market cap $36.44B), while Vanguard Mega Cap Growth ETF trades at $90.26. The key difference: Alcon AG pays a 0.48% dividend while Vanguard Mega Cap Growth ETF pays none, and Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | MGK | |
|---|---|---|
Market Cap | $36.44B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $90.12 | $92.06 |
52-Week Low | $62.02 | $70.70 |
Enterprise Value | $40.28B | — |
Dividend Yield | 0.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.525, down 0.14% on the day, with a bullish technical signal from moving averages and positive analyst sentiment. Recent Q2 2026 earnings beat estimates, with revenue of $10.4 billion in 2025 and a net income margin of 5.92%. The company raised its 2026 profitability outlook, citing tariff relief and strong product launches.
The stock offers a 17.9% upside to the consensus price target of $86.67, supported by bullish analyst ratings and improving cash flow trends. Key risks include elevated P/E valuation at 57.52 and potential macroeconomic pressures on medical device demand. Earnings growth and execution on new products remain critical for sustained momentum.
MGK trades at $90.30, down 0.36% on the day, with technical indicators showing a bullish trend supported by moving averages but overbought RSI readings. The ETF maintains strong institutional interest, with Bay Colony Advisory Group increasing its stake by 378.7% in the latest quarter. Recent news highlights MGK's superior five-year returns compared to small-cap alternatives, though with higher volatility due to its concentrated mega-cap tech focus.
MGK offers exposure to large-cap growth stocks with a low 0.05% expense ratio, delivering strong historical performance but facing concentration risk in technology sectors. The ETF's outlook remains positive given its track record of beating the S&P 500, though investors should monitor tech sector volatility and potential valuation pressures in mega-cap names.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
